Article

ISTA acquires rights to 3 ophthalmic compounds

Irvine, CA-ISTA Pharmaceuticals, Irvine, CA, entered into an agreement with AcSentient Inc. under which ISTA will acquire rights to three late-stage ophthalmology compounds.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Tiimes) EyeCon 2025: Sruthi Arepalli, MD, spotlights a deep dive orbital tour of the eye
Related Content
New company OpZira formed following Alcon’s acquisition of LumiThera
September 12th 2025

New company OpZira formed following Alcon’s acquisition of LumiThera

3 Things You Should Know About the GA Pipeline
September 12th 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

Alcon announces launch of wavelight plus, fully personalized LASIK treatment, in US and Canada
September 12th 2025

Alcon announces launch of wavelight plus, fully personalized LASIK treatment, in US and Canada

3 Things You Should Know About the GA Pipeline
September 12th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Effects of calcium channel blockers on visual field progression in glaucoma patients
September 12th 2025

Effects of calcium channel blockers on visual field progression in glaucoma patients

Study links AMD to higher cardiovascular disease mortality in high-risk patients
September 12th 2025

Study links AMD to higher cardiovascular disease mortality in high-risk patients

© 2025 MJH Life Sciences

All rights reserved.